Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Sowmya Andole & Sirisha Senthil. (2023) Ocular Surface Disease and Anti-Glaucoma Medications: Various features, Diagnosis, and Management Guidelines. Seminars in Ophthalmology 38:2, pages 158-166.
Read now
Read now
Andreas Katsanos, Ivano Riva, Banu Bozkurt, Gábor Holló, Luciano Quaranta, Francesco Oddone, Murat Irkec, Gordon N. Dutton & Anastasios G. Konstas. (2022) A new look at the safety and tolerability of prostaglandin analogue eyedrops in glaucoma and ocular hypertension. Expert Opinion on Drug Safety 21:4, pages 525-539.
Read now
Read now
Karen Walsh & Lyndon Jones. (2019) The use of preservatives in dry eye drops. Clinical Ophthalmology 13, pages 1409-1425.
Read now
Read now
Martina Cristaldi, Melania Olivieri, Gabriella Lupo, Carmelina D. Anfuso, Salvatore Pezzino & Dario Rusciano. (2018) N-hydroxymethylglycinate with EDTA is an efficient eye drop preservative with very low toxicity: an in vitro comparative study. Cutaneous and Ocular Toxicology 37:1, pages 71-76.
Read now
Read now
Luciano Quaranta, Ivano Riva, Andreas Katsanos, Irene Floriani, Marco Centofanti & Anastasios G P Konstas. (2015) Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure. Clinical Ophthalmology 9, pages 633-643.
Read now
Read now
Gemma Caterina Maria Rossi, Luigia Scudeller, Teresa Rolle, Gian Maria Pasinetti & Paolo Emilio Bianchi. (2015) From benzalkonium chloride-preserved Latanoprost to Polyquad-preserved Travoprost: a 6-month study on ocular surface safety and tolerability. Expert Opinion on Drug Safety 14:5, pages 619-623.
Read now
Read now
Articles from other publishers (19)
Anne Hedengran, Josefine Freiberg, Pernille May Hansen, Gerard Boix-Lemonche, Tor P. Utheim, Darlene A. Dartt, Goran Petrovski, Steffen Heegaard & Miriam Kolko. (2024) Comparing the effect of benzalkonium chloride-preserved, polyquad-preserved, and preservative-free prostaglandin analogue eye drops on cultured human conjunctival goblet cells. Journal of Optometry 17:1, pages 100481.
Crossref
Crossref
Anne Hedengran Nagstrup. (2023) The use of benzalkonium chloride in topical glaucoma treatment. Acta Ophthalmologica 101:S278, pages 3-21.
Crossref
Crossref
Elsa Wilma Böhm, Francesco Buonfiglio, Anna Maria Voigt, Philipp Bachmann, Tarek Safi, Norbert Pfeiffer & Adrian Gericke. (2023) Oxidative stress in the eye and its role in the pathophysiology of ocular diseases. Redox Biology 68, pages 102967.
Crossref
Crossref
Anne Hedengran & Miriam Kolko. (2023) The molecular aspect of anti-glaucomatous eye drops - are we harming our patients?. Molecular Aspects of Medicine 93, pages 101195.
Crossref
Crossref
Judy Weng, Michael K. Fink & Ajay Sharma. (2023) A Critical Appraisal of the Physicochemical Properties and Biological Effects of Artificial Tear Ingredients and Formulations. International Journal of Molecular Sciences 24:3, pages 2758.
Crossref
Crossref
Katarzyna Asendrych-Wicik, Jakub Zarczuk, Katarzyna Walaszek, Tomasz Ciach & Magdalena Markowicz-Piasecka. (2023) Trends in development and quality assessment of pharmaceutical formulations - F2α analogues in the glaucoma treatment. European Journal of Pharmaceutical Sciences 180, pages 106315.
Crossref
Crossref
Anne Hedengran, Josefine Clement Freiberg, Pernille May Hansen, Jette Jacobsen, Susan Weng Larsen, Stine Harloff‐Helleberg, Kristine Freude, Gerard Boix‐Lemonche, Goran Petrovski, Steffen Heegaard & Miriam Kolko. (2022) Generic benzalkonium chloride‐preserved travoprost eye drops are not identical to the branded polyquarternium‐1‐preserved travoprost eye drop. Acta Ophthalmologica 100:7, pages 819-827.
Crossref
Crossref
Fredrik Fineide, Neil Lagali, Muhammed Yasin Adil, Reiko Arita, Miriam Kolko, Jelle Vehof & Tor P. Utheim. (2022) Topical glaucoma medications – Clinical implications for the ocular surface. The Ocular Surface 26, pages 19-49.
Crossref
Crossref
Omer Ersin Muz, Kenan Dagdelen, Tuncay Pirdal & Mete Guler. (2021) Comparison of BAK-preserved latanoprost and polyquad-preserved travoprost on ocular surface parameters in patients with glaucoma and ocular hypertension. International Ophthalmology 41:11, pages 3825-3835.
Crossref
Crossref
Avani Kathuria, Kiumars Shamloo, Vishal Jhanji & Ajay Sharma. (2021) Categorization of Marketed Artificial Tear Formulations Based on Their Ingredients: A Rational Approach for Their Use. Journal of Clinical Medicine 10:6, pages 1289.
Crossref
Crossref
Erin StahlDominique Bremond-GignacTheresa LandryMike CurtisKinfemichael GedifSami Al ShahwanEl Roy Dixon. (2017) Pharmacokinetics and Safety of Travoprost 0.004% Ophthalmic Solution Preserved with Polyquad in Pediatric Patients with Glaucoma. Journal of Ocular Pharmacology and Therapeutics 33:5, pages 361-365.
Crossref
Crossref
Sabyasachi Maiti, Sayantan Sadhukhan & Paromita Bakshi. 2016. Nano-Biomaterials For Ophthalmic Drug Delivery. Nano-Biomaterials For Ophthalmic Drug Delivery
253
276
.
Joao F. Lopes, Douglas A. Hubatsch & Patricia Amaris. (2015) Effect of benzalkonium chloride–free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study. BMC Ophthalmology 15:1.
Crossref
Crossref
Fernando Pérez-Roca, Esther Rodrigo-Morales, Ingrid Garzón, Ana-Celeste Oliveira, Miguel-Ángel Martín-Piedra, Víctor Carriel, Ana-Isabel Ortiz-Pérez, Indalecio Sánchez-Montesinos, Antonio Campos & Miguel Alaminos. (2015) Effects of Four Formulations of Prostaglandin Analogs on Eye Surface Cells. A Comparative Study. PLOS ONE 10:6, pages e0129419.
Crossref
Crossref
Betül İlkay Sezgin AkçayEsra GüneyTahir Kansu BozkurtCumhur Selçuk TopalJülide Canan Umurhan AkkanCihan Ünlü. (2014) Effects of Polyquaternium- and Benzalkonium-Chloride-Preserved Travoprost on Ocular Surfaces: An Impression Cytology Study. Journal of Ocular Pharmacology and Therapeutics 30:7, pages 548-553.
Crossref
Crossref
Manlong XuJacob G. SivakDavid J. McCanna. (2013) Comparison of the Effects of Ophthalmic Solutions on Human Corneal Epithelial Cells Using Fluorescent Dyes. Journal of Ocular Pharmacology and Therapeutics 29:9, pages 794-802.
Crossref
Crossref
Makoto Aihara, Hiromi Oshima & Makoto Araie. (2012) Effects of SofZia‐preserved travoprost and benzalkonium chloride‐preserved latanoprost on the ocular surface – a multicentre randomized single‐masked study. Acta Ophthalmologica 91:1.
Crossref
Crossref
K.K. Huber-van der Velden, H. Thieme & M. Eichhorn. (2012) Morphologische Ver?nderungen durch Konservierungsmittel in AugentropfenMorphological alterations induced by preservatives in eye drops. Der Ophthalmologe 109:11, pages 1077-1081.
Crossref
Crossref
Jess T. Whitson & W. Matthew Petroll. (2012) Corneal Epithelial Cell Viability Following Exposure to Ophthalmic Solutions Containing Preservatives and/or Antihypertensive Agents. Advances in Therapy 29:10, pages 874-888.
Crossref
Crossref